Keep up with the latest headlines in dermatology from the past week, including Johnson & Johnson's acquisition of Proteologix, a review of sunscreen approvals and efficacy, and more.
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ.